Stefania L. Paolini

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Likelihood of aggressive PK/PD target attainment of continuous-infusion beta-lactams during the first week of treatment of febrile neutropenia: findings from a 1-year prospective, monocentric study in onco-haematological patients.

Likelihood of aggressive PK/PD target attainment of continuous-infusion beta-lactams during the first week of treatment of febrile neutropenia: findings from a 1-year prospective, monocentric study in onco-haematological patients.

Journal: The Journal of antimicrobial chemotherapy

Published: February 11, 2026

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.

Journal: Cancers

Published: March 28, 2025

Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction.

Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction.

Journal: International journal of molecular sciences

Published: December 18, 2024

Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms.

Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms.

Journal: Advances in biological regulation

Published: November 09, 2024

Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study.

Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 03, 2024

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.

Journal: The Lancet. Haematology

Published: May 10, 2024

Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human Blood.

Detection of Cancer Stem Cells in Normal and Dysplastic/Leukemic Human Blood.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: March 13, 2024

Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.

Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.

Journal: Clinical lymphoma, myeloma & leukemia

Published: November 14, 2023

Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression.

Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression.

Journal: Advances in biological regulation

Published: November 10, 2023

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.

Journal: Lancet (London, England)

Published: March 15, 2023

Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis.

Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis.

Journal: Cancers

Published: February 02, 2023

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Journal: American journal of hematology

Published: January 22, 2023

Showing 1-12 of 60

Last Updated: 09/26/2026